^
Association details:
| Biomarker: | CXCL8 elevation |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929)
Published date:
08/18/2020
Excerpt:
A Phase I clinical trial (GOG-9929) examined the safety and efficacy of adjuvant immune modulation therapy with the checkpoint inhibitor ipilimumab (anti-CTLA4) following chemoradiation therapy (CRT) for newly diagnosed node-positive human papillomavirus (HPV)-related cervical cancer. Elevation in levels of tumor-promoting circulating cytokines (TNFα, IL-6, IL-8) post-CRT were significantly associated with worse progression-free survival.
DOI:
10.1158/1078-0432.CCR-20-0776
